Journal of the American Society of Nephrology : JASN · 2026
Eupalinolide B Ameliorates Diabetic Kidney Disease via Inhibition of Cell Division Cycle 37-Mediated Inflammatory Pathways.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Huiying, Li Guanjun, Huang Ling, Fan Tianyun, Zhang Ying, Zhang Junzhe, Gu Liwei, Wang Jianyou, Hu Li, Tang Huan, Song Yali, Luo Qingming, Wang Jigang
Аннотация
KEY POINTS: A natural sesquiterpene lactone compound Eupalinolide B protected against diabetic kidney disease. Eupalinolide B targeted cell division cycle 37 protein and disrupted the interaction between cell division cycle 37 with heat shock protein 90. The renoprotective effects of Eupalinolide B were dependent on cell division cycle 37-mediated inflammatory pathways in diabetic kidney disease.
BACKGROUND: Diabetic kidney disease (DKD) is a major complication of diabetes, driven by chronic inflammation throughout its initiation and progression. Developing effective novel therapeutics is urgently needed. Eupalinolide B, a natural small compound derived from Eupatorium lindleyanum DC ., has multiple bioactive properties, notably antitumor and anti-inflammatory activities. However, the therapeutic potential of Eupalinolide B for DKD remains unclear. This study was to investigate the potential effects, direct targets, and pharmacologic mechanisms of Eupalinolide B against DKD, and discover novel therapeutic targets in the progression of DKD.
METHODS: The therapeutic effects of Eupalinolide B were assessed in high glucose-induced rat mesangial (HBZY-1) cells and db/db diabetic mice. Targeting and binding site engagement of Eupalinolide B was validated through activity-based protein profiling technology, pull-down assay, surface plasmon resonance analysis, and high-resolution mass spectrometry analysis. The target protein was knocked down to investigate its role in DKD-related inflammation and determine whether Eupalinolide B's renoprotective effects depend on the protein. The impact of Eupalinolide B on protein-protein interactions was examined using immunoblotting, immunohistochemistry, immunofluorescence, and coimmunoprecipitation assays.
RESULTS: Eupalinolide B was observed to ameliorate the glomerular filtration dysfunction and histopathologic damage in db/db mice and suppress NF-κB and mitogen-activated protein kinase proinflammatory pathways in both high glucose-induced HBZY-1 cells and db/db mice. In addition, we found that Eupalinolide B directly bound to cysteine 64 and 234 residues of cell division cycle 37 (CDC37), the essential cochaperone of heat shock protein 90 (HSP90). Mechanistically, by targeting CDC37, Eupalinolide B disrupted the interaction between CDC37 and HSP90, consequently blocking downstream proinflammatory signaling upon high glucose induction in HBZY-1 cells.
CONCLUSIONS: Eupalinolide B was identified as a novel CDC37-targeting agent with renoprotective and anti-inflammatory effects against DKD that functions by inhibiting CDC37-HSP90 interaction.
BACKGROUND: Diabetic kidney disease (DKD) is a major complication of diabetes, driven by chronic inflammation throughout its initiation and progression. Developing effective novel therapeutics is urgently needed. Eupalinolide B, a natural small compound derived from Eupatorium lindleyanum DC ., has multiple bioactive properties, notably antitumor and anti-inflammatory activities. However, the therapeutic potential of Eupalinolide B for DKD remains unclear. This study was to investigate the potential effects, direct targets, and pharmacologic mechanisms of Eupalinolide B against DKD, and discover novel therapeutic targets in the progression of DKD.
METHODS: The therapeutic effects of Eupalinolide B were assessed in high glucose-induced rat mesangial (HBZY-1) cells and db/db diabetic mice. Targeting and binding site engagement of Eupalinolide B was validated through activity-based protein profiling technology, pull-down assay, surface plasmon resonance analysis, and high-resolution mass spectrometry analysis. The target protein was knocked down to investigate its role in DKD-related inflammation and determine whether Eupalinolide B's renoprotective effects depend on the protein. The impact of Eupalinolide B on protein-protein interactions was examined using immunoblotting, immunohistochemistry, immunofluorescence, and coimmunoprecipitation assays.
RESULTS: Eupalinolide B was observed to ameliorate the glomerular filtration dysfunction and histopathologic damage in db/db mice and suppress NF-κB and mitogen-activated protein kinase proinflammatory pathways in both high glucose-induced HBZY-1 cells and db/db mice. In addition, we found that Eupalinolide B directly bound to cysteine 64 and 234 residues of cell division cycle 37 (CDC37), the essential cochaperone of heat shock protein 90 (HSP90). Mechanistically, by targeting CDC37, Eupalinolide B disrupted the interaction between CDC37 and HSP90, consequently blocking downstream proinflammatory signaling upon high glucose induction in HBZY-1 cells.
CONCLUSIONS: Eupalinolide B was identified as a novel CDC37-targeting agent with renoprotective and anti-inflammatory effects against DKD that functions by inhibiting CDC37-HSP90 interaction.